Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2016

View Archived Issues

Patients with atopic dermatitis dosed in phase I trial of MOR-106

Mouse model created using VPS35 gene mutation linked to Parkinson's disease

Intra-Cellular reports topline results from second phase III study of ITI-007 in schizophrenia

Tracon Pharmaceuticals starts collaboration with Janssen for TRC-253 and TRC-694

NAMPT may be useful as a biomarker for PD

Amgen reports topline data from phase III ARISE trial of erenumab to prevent episodic migraine

miRNAs show potential as biomarkers in liver fibrosis

CD1a is a potential new therapeutic target in inflammatory skin disease

The long non-coding RNA Morrbid is a promising new therapeutic target for inflammatory disorders

Eleventa completes patient enrollment for phase III trial of timapiprant

Adaptimmune Therapeutics and MD Anderson form cancer immunotherapy alliance

Pfizer completes acquisition of Medivation

Cellular Dynamics International launches new venture, Opsis Therapeutics

4SC Discovery patents KCNA3 channel blockers

Daiichi Sankyo to acquire license for technology platforms from Zymeworks

Marinus reports promising data from phase II trial of ganaxolone in PCDH19 pediatric epilepsy

Arbutus Biopharma reports interim results from phase II trial of ARB-1467 in chronic HBV

Vectus Biosystems reports development of vasodilating agents

Dermata Therapeutics reports findings from phase I trial of DMT-210 in acne rosacea

Kyung Hee University describes mPGES-1 inhibitors

Aurigene Discovery Technologies presents CDK inhibitors

Washington University announces HGFA inhibitors

11beta-HSD1 inhibitor alleviates muscle pain and mechanical allodynia in vivo

Phase IIb trial of Genocea's GEN-003 achieves primary endpoint

Recombinant human lubricin improves symptoms of dry eye disease

Amgen and Arrowhead Pharmaceuticals sign cardiovascular license and collaboration agreements

Hanmi Pharmaceutical enters agreement with Genentech

Mikeluna approved in Japan for glaucoma and intraocular hypertension

First patient dosed in phase I clinical study of PF-06840003

Boehringer Ingelheim and ViraTherapeutics to develop next generation oncolytic virus platform

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...